Solid Tumor Antibody-Drug Conjugate (ADC) Enfortumab Vedotin to be Evaluated as a Monotherapy in Patients Previously Treated with a Checkpoint Inhibitor

Astellas ranked in recognition of its commitment and support for working mothers

- Enzalutamide is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in this patient population in a randomized, controlled clinical trial

If approved, the combination therapy could potentially offer a new treatment option for patients whose overactive bladder symptoms are not adequately controlled on monotherapy

Winner will attend live taping of ABC's "Dancing with the Stars"

For the third consecutive year, the pharmaceutical company was named to the 2017 Great Place to Work® ranking among medium-sized multinational businesses across all industries in the country

Moyra Knight, Andrew Lewis and Karl Uhlendorf named to key roles

Astellas to Retain Certain Promising Antibody-Drug Conjugate R&D Programs of Agensys

Astellas recognized by Great Place to Work® Institute

David Musselman and Lynn Gerber named to key regional sales roles

Initiative part of Astellas’ ongoing commitment to communities, veterans and their families through its Living Smart social responsibility platform

Caroline Walkinshaw and Jacquelyn Bonnell named to key global and regional senior roles

Data Supported Initiation of Currently Enrolling Pivotal Phase 3 ADMIRAL Trial

The challenge is open to nearly anyone with a tangible, unique idea to improve cancer care

Employees also raised nearly $60K at Second Annual “One Astellas Spirit Run”

- Amendment accelerates anticipated PROSPER top-line results by two years -